Clinical trials: Mental
Alzheimer's Disease
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- ENGAGE (NCT02477800)
- Testing
- Aducanumab (BIIB037)
- Where
- 181 sites in United States, Australia and 12 more
- Volunteers
- 1,653 people
- Sponsor
- Biogen
Schizophrenia
Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate
The primary objective of this study is to explore hospitalization (number, length and reasons for psychiatric hospitalizations) in young, adult, newly diagnosed schizophrenia participants during the first 12 months of treatment…
- Trial name
- NCT02532842
- Where
- 7 sites in Croatia, Russia and 1 more
- Volunteers
- 90 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Mild Cognitive Impairment, Healthy Aging
A Novel Computer-Based Functional Skills Assessment and Training Program
People with cognitive impairments such as Mild Cognitive Impairment (MCI), often experience difficulty performing everyday routine activities.
- Trial name
- NCT04679441
- Testing
- The Computerized Functional Skills Assessment and Training Program, Brain HQ Double Decision
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- i-Function, Inc.
Major Depressive Disorder
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
The primary objective of this study was to compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) after 24 weeks of treatment.
- Trial name
- NCT01148472
- Testing
- Escitalopram, Duloxetine
- Volunteers
- 294 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
The primary objectives of this study are to evaluate the absolute bioavailability of a single, fixed sub-cutaneous (SC) dose of aducanumab compared with a single, weight-based intra-venous (IV) dose in healthy participants and to…
- Trial name
- NCT02782975
- Testing
- aducanumab
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Sleep Apnea, Sleep Apnea, Obstructive
Proof-of-Concept Study to Determine the Flow Changes When Stimulating Two Neural Targets for the Treatment of Obstructive Sleep Apnea
This proof-of-concept study will evaluate the impact of surgically placing and stimulating the hypoglossal nerve and/or a second neural target Ansa Cervicalis, with a set of off-the-shelf electrode arrays.
- Conditions
- Sleep Apnea, Sleep Apnea, Obstructive, Sleep Disorder, Sleep Apnea Syndromes
- Trial name
- NCT06415981
- Testing
- Hypoglossal nerve and/or Ansa Cervicalis stimulation
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Invicta Medical Inc.
Depressive Disorder, Major
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-RWE (NCT05841030)
- Testing
- No Intervention
- Where
- 95 sites in United States, Argentina and 9 more
- Volunteers
- 545 people
- Sponsor
- Janssen Research & Development, LLC
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Restless Legs Syndrome
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are: 1. Reduce or eliminate the symptoms of restless leg syndrome. 2.
- Trial name
- NCT06570941
- Testing
- Chylobinoid Topical Cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Synthonics Inc
Sleep Deprivation, Insufficient Sleep Syndrome
Pilot Study Comparing the Effectiveness of Two Different Methods of Acoustic Stimulation
This study is a randomized, single-blind, sham-controlled pilot cross-over trial comparing the feasibility, and efficacy of 2 nights of in lab use with active versus sham conditions in adults with sleep restricted schedules.
- Conditions
- Sleep Deprivation, Insufficient Sleep Syndrome, Healthy
- Trial name
- NCT03600194
- Testing
- PowerSleep Stim, Northwestern Stim
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Philips Respironics
Alcohol Aftereffects, Anxiety
A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects.
This study assesses the effectiveness of JoyRise Recovery Powder in reducing alcohol aftereffects, cognitive impairment, and anxiousness among participants aged 35-54 who consume alcohol.
- Conditions
- Alcohol Aftereffects, Anxiety, Cognitive Impairment
- Trial name
- NCT06575972
- Testing
- JoyRise Recovery Powder
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Joyrise
PTSD
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD.
- Trial name
- NCT03110575
- Testing
- TNX-102 SL
- Where
- 32 sites in United States
- Volunteers
- 190 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) for the treatment of Attention Deficit…
- Trial name
- NCT00269802
- Testing
- OROS methylphenidate HCl, Ritalin
- Sponsor
- Alza Corporation, DE, USA
Major Depressive Disorder
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing…
- Trial name
- NCT01437657
- Testing
- RO4917523 0.5 mg, RO4917523 1.5 mg
- Where
- 76 sites in United States, Chile and 7 more
- Volunteers
- 319 people
- Sponsor
- Hoffmann-La Roche
Mental Energy, Stress
The Cracking Consciousness Study With Monroe & Neuphoria
You've explored the Monroe Focus levels. But, Bob Monroe said, "You might believe something, but you won't understand it until you can measure it with objective data." Now, for the first time, we can measure them.
- Trial name
- NCT07256665
- Testing
- Neuphoria Wearable
- Where
- United States
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males
To assess the safety and tolerability of ascending single oral doses of SAM-315, an investigational drug, in healthy Japanese male subjects.To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-315…
- Trial name
- NCT00480467
- Testing
- SAM-315
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old.
- Trial name
- NCT05729373
- Testing
- SEP-363856
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 434 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Post-Traumatic Stress Disorder, PTSD
Software as a Medical Device for the Treatment of Patients With PTSD
To evaluate the efficacy and safety of Software as a Medical Device in patients with Post-Traumatic Stress Disorder (PTSD)
- Trial name
- NCT06589505
- Testing
- Software as a Medical Device
- Where
- 35 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Otsuka Medical Devices Co., Ltd. Japan
Opioid-use Disorder
Technology for MAT in Primary Care - Phase 2
With over 72,000 overdose deaths in 2017, of which 47,600 are attributable to opioid overdose, the opioid epidemic has become North America's most widespread behavioral public health problem.
- Trial name
- NCT05017272
- Testing
- Opioid Addiction Recovery Support Software Platform
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Q2i, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.